Holen Sie sich die Stockscreener-App
56.59
3.22%
-1.88
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$58.47
Offen:
$58
24-Stunden-Volumen:
1.25M
Relative Volume:
0.51
Marktkapitalisierung:
$5.26B
Einnahmen:
$536.20M
Nettoeinkommen (Verlust:
$-45.64M
KGV:
-105.82
EPS:
-0.5348
Netto-Cashflow:
$-28.94M
1W Leistung:
-0.58%
1M Leistung:
+21.07%
6M Leistung:
+63.65%
1J Leistung:
+241.93%
1-Tages-Spanne:
$55.00
$58.48
1-Wochen-Bereich:
$55.00
$59.69
52-Wochen-Spanne:
$15.03
$60.10
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
56.59 | 5.26B | 536.20M | -45.64M | -28.94M | -0.5348 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-31 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Travere Therapeutics Accounting Chief Sandra Calvin to Retire in 2027 - Moomoo
Why (TVTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Travere Therapeutics, Inc. Files Form 8-K with SEC: Key Details on Company and Stock Listing for July 2026 - Minichart
Sandra Calvin to Retire as Travere Therapeutics CAO; John Torell Named Successor - TradingView
Travere Therapeutics (NASDAQ: TVTX) plans CAO transition as Sandra Calvin retires - Stock Titan
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Travere Therapeutics Inc. (TVTX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
US FDA approves Vera's kidney disease drug - Reuters
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - Macau Business
Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX) - TradingView
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy - AOL.com
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress - AOL.com
Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative? - simplywall.st
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics Receives Notice of Allowance from the U.S. P - The National Law Review
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Understanding Momentum Shifts in (TVTX) - Stock Traders Daily
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Enterprise value to revenue forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Price to earnings forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Thera - The National Law Review
Price to sales forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
TVTX Maintained by Guggenheim -- Price Target Raised to $65 - GuruFocus
TVTX Forecast — Price Target — Prediction for 2027 - TradingView
Travere Therapeutics stock hits 52-week high at 56.9 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 56.9 USD - Investing.com
Travere Therapeutics Inc (TVTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Travere Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4 - Stock Titan
TVTX Maintains by Wedbush -- Price Target Raised to $61.00 - GuruFocus
Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says - marketscreener.com
Travere and Everest Medicines Strike $1.1 Billion Rare Kidney Disease Deal - The Healthcare Technology Report.
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $49 to $67 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):